Is Loxo Oncology, Inc. (LOXO) a Buy? The Stock Reaches All Time High Today

April 17, 2018 - By Margaret Downey

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

Investors sentiment decreased to 0.97 in Q4 2017. Its down 0.76, from 1.73 in 2017Q3. It is negative, as 29 investors sold Loxo Oncology, Inc. shares while 43 reduced holdings. 23 funds opened positions while 47 raised stakes. 124.82 million shares or 329.48% more from 29.06 million shares in 2017Q3 were reported.
2.09M were accumulated by Wellington Management Grp Llp. Sands Capital Mngmt Llc accumulated 2.27M shares. Lazard Asset Management Limited Liability Company reported 0% stake. Strs Ohio holds 1,000 shares or 0% of its portfolio. 458 are held by Financial Bank Of Montreal Can. Denver Advisors Ltd Llc holds 0.02% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO) for 4,692 shares. Tocqueville Asset Mngmt Limited Partnership stated it has 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Virtu Financial Limited Liability Com accumulated 10,109 shares. Metropolitan Life Com reported 0.01% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Bvf Il owns 0.04% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 4,386 shares. Prudential reported 38,070 shares. Rhenman Prtn Asset has invested 1.03% in Loxo Oncology, Inc. (NASDAQ:LOXO). Foresite Cap Management Ii Limited Company has 0.35% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 11,900 shares. Opaleye Management reported 176,300 shares or 4.75% of all its holdings. Pictet Asset Mngmt Ltd, United Kingdom-based fund reported 220,764 shares.

Since December 8, 2017, it had 0 insider buys, and 16 sales for $70.72 million activity. $223,262 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Burstein Jennifer on Tuesday, March 13. On Monday, February 12 the insider Bilenker Joshua H. sold $1.45 million. The insider AISLING CAPITAL III LP sold $20.13M. 3,082 Loxo Oncology, Inc. (NASDAQ:LOXO) shares with value of $250,240 were sold by Van Naarden Jacob. The insider Bonita David P sold $20.63M. Naider Avi Z. sold $1.50M worth of stock.

The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) reached all time high today, Apr, 17 and still has $142.03 target or 9.00 % above today’s $130.30 share price. This indicates more upside for the $3.91 billion company. This technical setup was reported by Barchart.com. If the $142.03 PT is reached, the company will be worth $352.17 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock decreased 2.36% or $3.15 during the last trading session, reaching $130.3. About 384,628 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 146.80% since April 17, 2017 and is uptrending. It has outperformed by 135.25% the S&P500.

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on May, 8. They expect $-0.44 EPS, up 54.17 % or $0.52 from last year’s $-0.96 per share. After $-0.69 actual EPS reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts -36.23 % EPS growth.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 8 analysts covering Loxo Oncology (NASDAQ:LOXO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Loxo Oncology had 13 analyst reports since October 20, 2017 according to SRatingsIntel. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Wednesday, March 21. The firm earned “Buy” rating on Thursday, November 2 by Stifel Nicolaus. The firm has “Buy” rating by Oppenheimer given on Thursday, February 22. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Strong Buy” rating given on Tuesday, November 14 by IFS Securities. The rating was upgraded by Morgan Stanley to “Overweight” on Monday, April 16. Citigroup maintained it with “Buy” rating and $151 target in Monday, March 5 report. The company was maintained on Wednesday, December 20 by BTIG Research. The firm has “Buy” rating given on Tuesday, November 14 by JMP Securities. Citigroup maintained it with “Buy” rating and $108 target in Thursday, November 16 report. Citigroup maintained the stock with “Buy” rating in Friday, October 20 report.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $3.91 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: